Logo image
IRO Home Research units Researcher Profiles
Sign in
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia
Journal article   Peer reviewed

Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia

Kamran Alimoghaddam, Ahmad Shariftabrizi, S Mohammad Tavangar, Mohammad Tavangar, Zohreh Sanaat, Shahrbanoo Rostami, Mohammad Jahani and Ardeshir Ghavamzadeh
Leukemia & lymphoma, Vol.47(1), pp.81-88
01/2006
DOI: 10.1080/10428190500300373
PMID: 16321832

View Online

Abstract

Immunohistochemistry Adolescent Adult Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Arsenic Trioxide Arsenicals - adverse effects Arsenicals - therapeutic use Bone Marrow - blood supply Bone Marrow - drug effects Bone Marrow - pathology Disease Progression Female Follow-Up Studies Humans Leukemia, Promyelocytic, Acute - drug therapy Leukocytosis - chemically induced Leukocytosis - pathology Male Middle Aged Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Oxides - adverse effects Oxides - therapeutic use Recurrence Remission Induction Survival Rate Time Factors Treatment Outcome

Details

Metrics

Logo image